Business

Pfizer’s recent decision to discontinue the development of its twice-daily weight loss pill, danuglipron, highlights the ongoing challenges faced by pharmaceutical companies in creating effective and safe treatments for obesity. While obese patients in clinical trials experienced significant weight loss with the drug, the high rates of adverse side effects were a cause for concern.
0 Comments
Ford Motor recently reinstated its 2023 guidance after withdrawing it the previous month due to labor strikes and negotiations with the United Auto Workers (UAW) union. The updated guidance includes adjusted earnings before interest and taxes (EBIT) of $10 billion to $10.5 billion and adjusted free cash flow of $5 billion to $5.5 billion. This
0 Comments